Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells
Open Access
- 17 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10), e46571
- https://doi.org/10.1371/journal.pone.0046571
Abstract
Cancer can be envisioned as a metabolic disease driven by pressure selection and intercellular cooperativeness. Together with anaerobic glycolysis, the Warburg effect, formally corresponding to uncoupling glycolysis from oxidative phosphorylation, directly participates in cancer aggressiveness, supporting both tumor progression and dissemination. The transcription factor hypoxia-inducible factor-1 (HIF-1) is a key contributor to glycolysis. It stimulates the expression of glycolytic transporters and enzymes supporting high rate of glycolysis. In this study, we addressed the reverse possibility of a metabolic control of HIF-1 in tumor cells. We report that lactate, the end-product of glycolysis, inhibits prolylhydroxylase 2 activity and activates HIF-1 in normoxic oxidative tumor cells but not in Warburg-phenotype tumor cells which also expressed lower basal levels of HIF-1α. These data were confirmed using genotypically matched oxidative and mitochondria-depleted glycolytic tumor cells as well as several different wild-type human tumor cell lines of either metabolic phenotype. Lactate activates HIF-1 and triggers tumor angiogenesis and tumor growth in vivo, an activity that we found to be under the specific upstream control of the lactate transporter monocarboxylate transporter 1 (MCT1) expressed in tumor cells. Because MCT1 also gates lactate-fueled tumor cell respiration and mediates pro-angiogenic lactate signaling in endothelial cells, MCT1 inhibition is confirmed as an attractive anticancer strategy in which a single drug may target multiple tumor-promoting pathways.Keywords
This publication has 58 references indexed in Scilit:
- Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and MetastasisCurrent Pharmaceutical Design, 2012
- Evidence for a stromal-epithelial “lactate shuttle” in human tumorsCell Cycle, 2011
- NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatmentProceedings of the National Academy of Sciences of the United States of America, 2010
- Development of HIF‐1 inhibitors for cancer therapyJournal of Cellular and Molecular Medicine, 2009
- Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding ActivityCancer Research, 2005
- Basigin (CD147) Is the Target for Organomercurial Inhibition of Monocarboxylate Transporter Isoforms 1 and 4Journal of Biological Chemistry, 2005
- Why do cancers have high aerobic glycolysis?Nature Reviews Cancer, 2004
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysisNature, 1999
- Mechanism of inhibition of fadu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chlorideInternational Journal of Cancer, 1994
- Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells.Journal of Biological Chemistry, 1979